CAT scan of brain, Alzheimer's disease (Credit: Getty Images)
March 8, 2024 03:42 PM ESTUpdated March 11, 09:34 AM
Pharma

Five ques­tions on the fu­ture of Lil­ly’s Alzheimer’s drug, from Dunn’s lega­cy to ARIA

Ryan Cross

Senior Science Correspondent

Zachary Brennan

Senior Editor

Just days ago, suc­cess in Eli Lil­ly’s 30-year pur­suit of an Alzheimer’s dis­ease drug seemed all but guar­an­teed. Now, the FDA’s 11th …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times